Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Abstract The development of novel immunotherapeutics for acute myeloid leukemia (AML) is hampered by the limited knowledge of tumor-expressed targets absent on non-malignant cells. We recently identified the RNA binding protein U5 small nuclear ribonucleoprotein 200 kDa (U5 snRNP200) as a novel antigen that is overexpressed on AML blasts in 50% of cases. As a non-canonical membrane protein lacking a transmembrane domain, a cofactor is required for surface expression.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.